soul study semaglutide Updates in Medicine | 🩺 Oral Cuts CV Risk in High-Risk T2DM – Trial (NEJM, Mar 2025) 🔗 Original article link in bio 📌 Key Highlights: 🔹 Forecasting Trial Milestones: A Predictive

This period allows for a good assessment of short-term efficacy and initial physiological responses

Your consultation, follow-up care, and prescription management are completed through secure telehealth without any in-person appointments

For healthcare professionals, this approval provides a new treatment option to help us address cardiovascular residual risk that remains for patients on current standard of care. Wegovy is now the first weight loss medication to also be approved to help prevent life-threatening cardiovascular events in adults with cardiovascular disease and either obesity or overweight, said John Sharretts, director of the Division of Diabetes, Lipid Disorders, and Obesity in the FDAs Center for Drug Evaluation and Research

It may also allow other serious arrhythmias to occur